<DOC>
	<DOCNO>NCT01143025</DOCNO>
	<brief_summary>The purpose study assess intraperitoneal nebulization Ropivacaine 50 mg , 100 mg 150 mg may prevent use morphine first day laparoscopic cholecystectomy .</brief_summary>
	<brief_title>Intraperitoneal Ropivacaine Nebulization Pain Control After Laparoscopic Surgery</brief_title>
	<detailed_description>Intraperitoneal aerosolization Bupivacaine 50 mg laparoscopic cholecystectomy prove significantly reduce postoperative pain , morphine consumption incidence postoperative nausea vomit comparison patient receive direct instillation Bupivacaine 50 mg placebo . Ropivacaine effectively administrate non-heating nebulizer ( AeronebPro® ) . In recent study group find nebulization Ropivacaine 30 mg AeronebPro® laparoscopic cholecystectomy significantly reduce postoperative pain morphine consumption . Nonetheless , patient still need strong opioid base analgesia surgery . We hypothesize intraperitoneal nebulization Ropivacaine 100 mg 150 mg ( maximum recommend dose adult 300 mg 3 mg/kg ) may prevent use morphine first day surgery maintain ropivacaine plasma level toxic concentration .</detailed_description>
	<mesh_term>Ropivacaine</mesh_term>
	<criteria>Females Males 1875 year old ASA Score IIII Scheduled laparoscopic cholecystectomy Free pain preoperative period Not use analgesic drug surgery Without cognitive impairment mental retardation Written inform consent Emergency/urgency surgery Postoperative admission intensive care unit Cognitive impairment mental retardation Progressive degenerative disease CNS Seizures chronic therapy antiepileptic drug Severe hepatic renal impairment Pregnancy lactation Allergy one specific drug study Acute infection inflammatory chronic disease Alcohol drug addiction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Laparoscopic Cholecystectomy</keyword>
	<keyword>Nebulization</keyword>
	<keyword>Ropivacaine</keyword>
</DOC>